Drugs that contain Netarsudil Mesylate
1. List of Rhopressa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(7 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2022 |
NCE-1 date: December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of RHOPRESSA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic